Rilonacept + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Pericarditis
Conditions
Recurrent Pericarditis
Trial Timeline
Jan 7, 2019 → Jun 30, 2022
NCT ID
NCT03737110About Rilonacept + Placebo
Rilonacept + Placebo is a phase 3 stage product being developed by Kiniksa Pharmaceuticals for Recurrent Pericarditis. The current trial status is completed. This product is registered under clinical trial identifier NCT03737110. Target conditions include Recurrent Pericarditis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03737110 | Phase 3 | Completed |
Competing Products
20 competing products in Recurrent Pericarditis